Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing
By implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored impact of TP53 mutations on tumor evolution and resistance mechanisms to ensartinib in ALK-positive non-small-cell lung cancer (NSCLC) patients.